<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525781</url>
  </required_header>
  <id_info>
    <org_study_id>Urinary bladder cancer.</org_study_id>
    <nct_id>NCT04525781</nct_id>
  </id_info>
  <brief_title>Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer</brief_title>
  <official_title>Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer at Assuit University Hospital From 2015 to 2019(Hospital Based Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To pinpoint the clinical ,epidimiological factors and clinical outcomes in urinary bladder&#xD;
      cancer patients attending to our department during 5 years period between 2015-2019.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bladder cancer is the ninth most common cancer throughout the world. The incidence of bladder&#xD;
      cancer is three to four times greater in men than in women. However, women are diagnosed with&#xD;
      more advanced disease at presentation and have less favorable outcomes after treatment.&#xD;
      Statistical data show that between 2002 and 2012, worldwide, the number of bladder cancers&#xD;
      increased from 375.000 to about 430.000 , while the mortality increased from 145.000 patients&#xD;
      in 2002 up to 165.000 patients in 2012. In the United States, bladder cancer is the fourth&#xD;
      most common cancer in males with an age-adjusted incidence rate of 37.3/100,000 person years&#xD;
      (PY) using the US standard population.&#xD;
&#xD;
      In developed countries, over 90% of the bladder cancer cases diagnosed are transitional cell&#xD;
      carcinoma (TCC), with squamous cell carcinoma (SCC), adenocarcinomas, and rare types of&#xD;
      bladder cancer comprising the remaining 10% of bladder cancer cases.&#xD;
&#xD;
      Exposures to tobacco smoke, occupational toxins, and environmental sources of heavy metals&#xD;
      such as arsenic are the major reported risk factors for TCC.&#xD;
&#xD;
      Unlike TCC, the main risk factors for SCC are not environmental exposures, but exposure to&#xD;
      infectious agents. Age, smoking, tumor stage and the treatment modalities such as surgery and&#xD;
      adjuvant chemotherapy were proved to affect the overall survival in patients with urinary&#xD;
      bladder cancer. Our study may give an important evidence about clinical, epidemiological&#xD;
      factors and clinical outcomes in urinary bladder cancer patients at Assuit University&#xD;
      Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of response in non muscle invasive,muscle invasive and metastatic bladder cancer.</measure>
    <time_frame>baseline</time_frame>
    <description>Analysis of patients data including risk factors and treatment and detection of response in each stage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival in bladder cancer in different stages</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Urinary Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        study initialy including about 150 patients with urinary bladder cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 :70&#xD;
&#xD;
          -  Histologically proved urinary bladder carcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 or more than 70&#xD;
&#xD;
          -  Patient not documented having bladder carcinoma with biopsy [cysyoscopic or operative]&#xD;
&#xD;
          -  Patient with synchronous or metachronous double primary&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rehab Osama Abdelmoboud</last_name>
    <phone>01064482770</phone>
    <email>Rehabosama620@gmail.com</email>
  </overall_contact>
  <link>
    <url>http://seer.cancer.gov/statfacts/.</url>
    <description>Surveillance Epidemiology End Results. Cancer Stat Facts Sheet</description>
  </link>
  <reference>
    <citation>Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.</citation>
    <PMID>15761078</PMID>
  </reference>
  <reference>
    <citation>Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol. 2016 Feb;69(2):300-10. doi: 10.1016/j.eururo.2015.08.037. Epub 2015 Sep 4. Review.</citation>
    <PMID>26346676</PMID>
  </reference>
  <reference>
    <citation>Murta-Nascimento C, Schmitz-Dr√§ger BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007 Jun;25(3):285-95. Review.</citation>
    <PMID>17530260</PMID>
  </reference>
  <reference>
    <citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.</citation>
    <PMID>25220842</PMID>
  </reference>
  <reference>
    <citation>Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015 Apr;29(2):177-89, vii. doi: 10.1016/j.hoc.2014.10.001. Review.</citation>
    <PMID>25836927</PMID>
  </reference>
  <reference>
    <citation>Zhao M, He XL, Teng XD. Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chin J Cancer Res. 2016 Feb;28(1):92-8. doi: 10.3978/j.issn.1000-9604.2016.02.05. Review.</citation>
    <PMID>27041931</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. Erratum in: CA Cancer J Clin. 2005 Jul-Aug;55(4):259.</citation>
    <PMID>15661684</PMID>
  </reference>
  <reference>
    <citation>Lynch CF, Cohen MB. Urinary system. Cancer. 1995 Jan 1;75(1 Suppl):316-29.</citation>
    <PMID>8001003</PMID>
  </reference>
  <reference>
    <citation>Golka K, Wiese A, Assennato G, Bolt HM. Occupational exposure and urological cancer. World J Urol. 2004 Feb;21(6):382-91. Epub 2003 Nov 26. Review.</citation>
    <PMID>14648102</PMID>
  </reference>
  <reference>
    <citation>Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer. 1986 Mar;53(3):399-405.</citation>
    <PMID>3964542</PMID>
  </reference>
  <reference>
    <citation>Shokeir AA. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 2004 Jan;93(2):216-20. Review.</citation>
    <PMID>14690486</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Rehab Osama Abdelmaboud</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

